Jinhe Biotechnology Co Ltd - Asset Resilience Ratio
Jinhe Biotechnology Co Ltd (002688) has an Asset Resilience Ratio of 0.02% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check 002688 strategic asset allocation to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2024)
This chart shows how Jinhe Biotechnology Co Ltd's Asset Resilience Ratio has changed over time. See net asset quality index of Jinhe Biotechnology Co Ltd to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Jinhe Biotechnology Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 002688 market cap overview.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥1.37 Million | 0.02% |
| Total Liquid Assets | CN¥1.37 Million | 0.02% |
Asset Resilience Insights
- Limited Liquidity: Jinhe Biotechnology Co Ltd maintains only 0.02% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Jinhe Biotechnology Co Ltd Industry Peers by Asset Resilience Ratio
Compare Jinhe Biotechnology Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603 |
Drug Manufacturers - Specialty & Generic | 11.60% |
|
SIMCERE PHARMAC. GRP LTD
F:S2P |
Drug Manufacturers - Specialty & Generic | 0.44% |
|
Curaleaf Holdings Inc.
TO:CURA |
Drug Manufacturers - Specialty & Generic | 3.73% |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755 |
Drug Manufacturers - Specialty & Generic | 24.59% |
|
Walvax BioTech
SHE:300142 |
Drug Manufacturers - Specialty & Generic | 2.20% |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091 |
Drug Manufacturers - Specialty & Generic | 26.36% |
|
Cronos Group Inc
TO:CRON |
Drug Manufacturers - Specialty & Generic | 69.94% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
Annual Asset Resilience Ratio for Jinhe Biotechnology Co Ltd (2016–2024)
The table below shows the annual Asset Resilience Ratio data for Jinhe Biotechnology Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.01% | CN¥553.12K ≈ $80.94K |
CN¥5.65 Billion ≈ $826.86 Million |
+0.00pp |
| 2023-12-31 | 0.01% | CN¥507.66K ≈ $74.29K |
CN¥5.45 Billion ≈ $798.06 Million |
+0.16pp |
| 2021-12-31 | -0.15% | CN¥-6.24 Million ≈ $-912.65K |
CN¥4.06 Billion ≈ $594.77 Million |
+0.26pp |
| 2020-12-31 | -0.41% | CN¥-13.97 Million ≈ $-2.04 Million |
CN¥3.38 Billion ≈ $494.14 Million |
-0.10pp |
| 2019-12-31 | -0.31% | CN¥-10.34 Million ≈ $-1.51 Million |
CN¥3.34 Billion ≈ $489.37 Million |
-0.37pp |
| 2018-12-31 | 0.06% | CN¥2.14 Million ≈ $313.21K |
CN¥3.34 Billion ≈ $488.07 Million |
+0.26pp |
| 2016-12-31 | -0.20% | CN¥-5.23 Million ≈ $-766.04K |
CN¥2.66 Billion ≈ $389.58 Million |
-- |
About Jinhe Biotechnology Co Ltd
Jinhe Biotechnology CO., LTD. produces and sells veterinary medicines in China and internationally. It offers chlortetracycline premixes; veterinary drug and powder series; disinfectants; and sprinklers. It also engages in the production and sales of feed and raw materials. The company was founded in 1990 and is headquartered in Hohhot, China.